Veracyte Inc

NASDAQ:VCYT   3:59:59 PM EDT
37.47
-0.72 (-1.88%)
Other Pre-Announcement

Veracyte Announces New Pivotal Clinical Validation Data At Asco Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection

Published: 05/19/2021 21:23 GMT
Veracyte Inc (VCYT) - Veracyte Announces New Pivotal Clinical Validation Data at Asco Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection.
Veracyte Inc - Expects to Begin Making Percepta Nasal Swab Test Available to a Select Number of Sites in Second Half of 2021.
Veracyte Inc - Co Aims to Adapt Percepta Nasal Swab Test on Ncounter Analysis System in 2022.